1829-33-0

Usage

Uses

Used in Pharmaceutical Industry:
3-CHLORO-5-HYDROXYBENZALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals due to its ability to participate in a wide range of organic reactions, contributing to the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-CHLORO-5-HYDROXYBENZALDEHYDE serves as a building block for the creation of compounds with pesticidal properties, aiding in the development of effective solutions for crop protection and enhancement of agricultural yields.
Used in Dye Industry:
3-CHLORO-5-HYDROXYBENZALDEHYDE is utilized in the production of dyes, where its chemical structure allows for the creation of colorants with specific properties, such as colorfastness and brightness, for use in various applications including textiles and printing inks.
Used in Organic Synthesis:
3-CHLORO-5-HYDROXYBENZALDEHYDE is employed as a versatile intermediate in organic synthesis, enabling the construction of a broad spectrum of organic compounds for research and commercial purposes, including the development of new materials and chemical entities.
Used in Biological Research:
3-CHLORO-5-HYDROXYBENZALDEHYDE is being investigated for its pharmacological properties, with potential applications in biological research to explore its effects on various biological systems and its use as a probe in understanding complex biological processes.

Upstream product

• 473923-97-6 3-chloro-5-hydroxybenzonitrile 
• 164650-68-4 3-methoxy-5-chlorobenzaldehyde 

Downstream Products

• 433940-20-6 3-chloro-5-difluoromethoxybenzaldehyde 
• 885270-34-8 3-chloro-5-(hydroxymethyl)phenol 
• 433938-81-9 3-chloro-5-(2,2,2-trifluoroethoxy)benzaldehyde 

Relevant academic research and scientific papers

AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS

The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the kinase ERK activity in particular ERK2 activity.

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION

According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen

MODIFIED RELEASE PHARMACEUTICAL FORMULATION

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.